Little Green Pharma Ltd engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.68|
|52 Week High||AU$0.33|
|52 Week Low||AU$1.02|
|1 Month Change||-3.57%|
|3 Month Change||-18.18%|
|1 Year Change||98.53%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||92.86%|
Recent News & Updates
Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position
After announcing healthy earnings, Little Green Pharma Ltd's ( ASX:LGP ) stock rose over the last week. While the...
|LGP||AU Pharmaceuticals||AU Market|
Return vs Industry: LGP exceeded the Australian Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: LGP exceeded the Australian Market which returned 24.4% over the past year.
Stable Share Price: LGP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: LGP's weekly volatility (6%) has been stable over the past year.
About the Company
Little Green Pharma Ltd engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally. It offers cannabis flower products. The company was incorporated in 2016 and is headquartered in West Perth, Australia.
Little Green Pharma Fundamentals Summary
|LGP fundamental statistics|
Is LGP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LGP income statement (TTM)|
|Cost of Revenue||AU$1.23m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.10|
|Net Profit Margin||351.30%|
How did LGP perform over the long term?See historical performance and comparison
Is Little Green Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LGP is good value based on its PE Ratio (6.5x) compared to the Oceanic Pharmaceuticals industry average (44.9x).
PE vs Market: LGP is good value based on its PE Ratio (6.5x) compared to the Australian market (20x).
Price to Earnings Growth Ratio
PEG Ratio: LGP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: LGP is good value based on its PB Ratio (1.7x) compared to the AU Pharmaceuticals industry average (3.7x).
How is Little Green Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGP's earnings are forecast to decline over the next 3 years (-101.1% per year).
Earnings vs Market: LGP's earnings are forecast to decline over the next 3 years (-101.1% per year).
High Growth Earnings: LGP's earnings are forecast to decline over the next 3 years.
Revenue vs Market: LGP's revenue (61.1% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: LGP's revenue (61.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LGP is forecast to be unprofitable in 3 years.
How has Little Green Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGP has a high level of non-cash earnings.
Growing Profit Margin: LGP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: LGP has become profitable over the past 5 years, growing earnings by 40.3% per year.
Accelerating Growth: LGP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: LGP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: LGP's Return on Equity (26.2%) is considered high.
How is Little Green Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: LGP's short term assets (A$54.0M) exceed its short term liabilities (A$15.9M).
Long Term Liabilities: LGP's short term assets (A$54.0M) exceed its long term liabilities (A$1.2M).
Debt to Equity History and Analysis
Debt Level: LGP's debt to equity ratio (12.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LGP's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: LGP's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if LGP's interest payments on its debt are well covered by EBIT.
What is Little Green Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LGP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LGP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Fleta Jennifer Solomon serves as Managing Director at Little Green Pharma Ltd. She serves as Director of Little Green Pharma Ltd since May 29, 2017. She joins Little Green Pharma Ltd in February 2017....
CEO Compensation Analysis
Compensation vs Market: Fleta's total compensation ($USD728.88K) is above average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Fleta's compensation has been consistent with company performance over the past year.
Experienced Board: LGP's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 75.5%.
Little Green Pharma Ltd's employee growth, exchange listings and data sources
- Name: Little Green Pharma Ltd
- Ticker: LGP
- Exchange: ASX
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$159.261m
- Shares outstanding: 235.94m
- Website: https://www.littlegreenpharma.com
Number of Employees
- Little Green Pharma Ltd
- Level 2
- Suite 2
- West Perth
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:30|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.